IPS HEART is the first induced pluripotent stem cell company to launch in 2014 around heart disease. With over $20 million+ of funded research, we were the first to publish our moon-shot approach showing extensive heart regeneration after heart attack with over 50%+ EF improvement vs control and a 70% reduction in fibrosis. We have created extensive new functional human heart muscle in our published studies thus validating our patented IPS small molecule platform approach. With a completed FDA PRE-IND meeting and GMP manufacturing, we plan to file the first IPS IND to start clinically in the United States.
Our Scientific Founder is the top 1% of all funded NIH Researchers with over $54 million in career NIH funding, 250 publications and is the recipient of the prestigious 10 year National Merit Award by the NIH. Together with our key clinical partner who leads the field clinically with the most cardiac stem cell clinical trials by a wide margin, both are cited as the top two American scientists in the field with the most high impact publications. Our Board includes the world's leading Cardiac Researchers including the only two Cardiologists who are out clinically in our field Dr. Philippe Menasche, Professor of Thoracic and Cardiovascular Surgery, University of Paris Descartes. Dr. Menasche has completed the worlds first pluripotent Phase I cardiomyocyte stem cell clinical trial in Paris showing strong proof of concep with no safety issues. Our other Advisor Dr. Yoshiki Sawa has just started the world's first IPS cardiomyocyte Phase I in Japan. Other Advisors include Dr. John Jefferies, Chairman of Cardiology & CV Institute Director at the University of Tennessee. We are fortunate to have 2 other publicly traded CEOs backing us and JPAL Advisor Kathy Tsokas who heads Regulatory for Regenerative Medicine at J&J.
IPS HEART replicated its pioneering small molecule IPS platform approach in a second disease by publishing for the first time new dystrophin + skeletal muscle for Duchenne Muscular Dystrophy. IPS HEART is the only IPS company to have published strong efficacy in 2 difficult diseases by creating new cardiac muscle and skeletal muscle for both heart disease and DMD.
Copyright © 2014 IPS HEART - All Rights Reserved.
Notice: Please ignore HR recruitment emails that are not from the domain "@ipsheart.com", they are not associated with IPS HEART.